Application for genes involved in regulation of HB-EGF expression as diagnostic markers and target molecules for breast cancer

• Project/Area Number: 22790536
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Laboratory medicine
• Research Institution: Fukuoka University
• Principal Investigator: YOTSUMOTO Fusanori 福岡大学, 医学部, 講師 (40533089)
• Project Period (FY): 2010 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: HB-EGF / 乳癌 / 腫瘍検査学

Research Abstract

In this study, we identified the gene(X) involved in regulation of the expression of HB-EGF, a target molecule of breast cancer therapy. The gene(X) enhanced translation of HB-EGF mRNA into protein by the function of binding the exon junctions of HB-EGF mRNA, resulting in increasing the tumorigenic potential in vivo model and associating with prognosis of breast cancer patients. Therefore, gene(X) might be a potent diagnostic marker and therapeutic target molecule for breast cancer as well as HB-EGF.

Research Products

• [Journal Article] Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA (2011)
  • Author(s): Hikita S, Yotsumoto F, Fukami T, Horiuchi S, Sanui A, Miyata K, Nam SO, Tsujioka H, Ueda T, Shirota K, Yoshizato T, Maeda K, Ishikawa T, Okuno Y, Kuroki M, Mekada E, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.31 Pages: 2553-2559
  • Peer Reviewed
• [Journal Article] Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia (2011)
  • Author(s): Kunami N, Yotsumoto F, Ishitsuka K, Fukami T, Odawara T, Manabe S, Ishikawa T, Tamura K, Kuroki M, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.31 Pages: 2483-2488
  • Peer Reviewed
• [Journal Article] A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer (2011)
  • Author(s): Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, Takahashi Y, Kondo H, Kuroki M, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.31 Pages: 2461-2465
  • Peer Reviewed
• [Journal Article] Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells (2011)
  • Author(s): Koshikawa N, Mizushima H, Minegishi T, Eguchi F, Yotsumoto F, Nabeshima K, Miyamoto S, Mekada E, Seiki M
  • Journal Title: Cancer Science Volume: Vol.102 Pages: 111-116
  • NAID: 10029288679
  • Peer Reviewed
• [Journal Article] A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Anti-Tumor Mechanisms Against Ovarian Cancer Cells (2011)
  • Author(s): Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H, Murakami T, Hori S, Shitara K, Mekada E
  • Journal Title: Clinical Cancer Research Volume: Vol.17 Pages: 6733-6741
  • Peer Reviewed
• [Journal Article] Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA (2011)
  • Author(s): Hikita S, Yotsumoto F, Fukami T, Horiuchi S, Sanui A, Miyata K, Nam S, Tsujioka H, Ueda T, Shirota K, Yoshizato T, Maeda K, Ishikawa T, Okuno Y, Kuroki M, Mekada E, Miyamoto S
  • Journal Title: Anticancer Research Volume: 31 Pages: 2553-2559
  • Peer Reviewed
• [Journal Article] HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer (2010)
  • Author(s): Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S
  • Journal Title: International Journal of Cancer Volume: Vol.127 Pages: 2707-2717
  • Peer Reviewed
• [Journal Article] Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer (2010)
  • Author(s): Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S
  • Journal Title: Cancer Science Volume: Vol.101 Pages: 2351-2360
  • NAID: 10027833378
  • Peer Reviewed
• [Journal Article] HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer (2010)
  • Author(s): Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.30 Pages: 3143-3149
  • Peer Reviewed
• [Journal Article] Emerging strategies for ErbB ligand-based targeted therapy for cancer (2010)
  • Author(s): Tsujioka H, Yotsumoto F, Shirota K, Horiuchi S, Yoshizato T, Kuroki M, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.30 Pages: 3107-3112
  • Peer Reviewed
• [Journal Article] Apoptosis as a possiblecandidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations (2010)
  • Author(s): Tsujioka H, Hachisuga T, Hikita S, Ueda T, Yotsumoto F, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S
  • Journal Title: Anticancer Research Volume: Vol.30 Pages: 3119-3123
  • Peer Reviewed
• [Journal Article] HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. (2010)
  • Author(s): Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S.
  • Journal Title: International Journal of Cancer Volume: 127 Pages: 2707-2717
  • Peer Reviewed
• [Journal Article] Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. (2010)
  • Author(s): Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S.
  • Journal Title: Cancer Science Volume: 101 Pages: 2351-2360
  • NAID: 10027833378
  • Peer Reviewed
• [Journal Article] HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. (2010)
  • Author(s): Sanui A, Yotsumoto F, Tsujioka H, Fukami T, Horiuchi S, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S.
  • Journal Title: Anticancer Research Volume: 30 Pages: 3143-3149
  • Peer Reviewed
• [Journal Article] Emerging strategies for ErbB ligand-based targeted therapy for cancer. (2010)
  • Author(s): Tsujioka H, Yotsumoto F, Shirota K, Horiuchi S, Yoshizato T, Kuroki M, Miyamoto S.
  • Journal Title: Anticancer Research Volume: 30 Pages: 3107-3112
  • Peer Reviewed
• [Journal Article] Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations. (2010)
  • Author(s): Tsujioka H, Hachisuga T, Hikita S, Ueda T, Yotsumoto F, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S.
  • Journal Title: Anticancer Research Volume: 30 Pages: 3119-3123
  • Peer Reviewed